[Therapeutic strategy for hepatic @entity3 of primary XXXX ].

@entity1 @entity694 @entity5 @entity3
PURPOSE: To analyze the clinical results of treatments for hepatic @entity3 of primary @entity694 for an evaluation of treatment strategies. MATERIALS AND METHODS: Two hundred and twenty-five @entity1 with only hepatic @entity3 of primary @entity694 ( @entity5 , 164 @entity1 : @entity5 , 61 @entity1 ) between 1983 and 1999 were studied. Of these 225 @entity1 , 68 @entity1 ( @entity5 , 39 @entity1 : @entity5 , 29 @entity1 ) were treated with curative resection. These 225 @entity1 were categorized into group A (chemotherapy only), group B (hepatic arterial infusion only), group C (curative resection + hepatic arterial infusion), and group D (curative resection only). The therapeutic results were compared. RESULTS: The five-year survival rate and five-year recurrence-free rate of 68 @entity1 with curative resection were 40.6% and 31.0%. By therapeutic modality, the five-year survival rate and five-year recurrence-free rate of the 36 @entity1 of group C were 40.7% and 29.5%, and those of the 32 @entity1 of group D were 43.4% and 33.0%, respectively. No significant difference was found between these two groups. However, in the @entity1 with @entity5 , the five-year survival rate and five-year recurrence-free rate of group C and group D were 65.7, 49.6% and 13.8, 15.9%, respectively. The results of group C were significantly better than those of group D. Recurrence was found in 36 @entity1 (52.2%). Among these @entity1 , 25 (36.8%) recurred within one year from the end of treatment(s). Twenty-one @entity1 (32.4) had the recurrence in the residual liver, and 14 (17.6%) had @entity3 to the lung. In group B, in which curative resection was impossible, the one-year and two-year survival rates in the @entity1 with @entity5 were good in comparison with those of group A. Herein we report two cases in which hepatic arterial infusion was effective. CONCLUSION: It is important to set aggressive resection and hepatic infusion as a fundamental treatment policy, and to perform not only hepatic infusion but to combine other treatments with consideration of the next recurrence.
